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Introduction
Immune-mediated food reactions are classified 
into IgE-mediated, non-IgE-mediated, or mixed 
reactions. In IgE-mediated cases, allergen-specific 
immunoglobulin E (IgE) antibodies induce the 
activation of mast cells and basophils, which in 
turn causes the release of histamine. The onset of 
typical clinical food allergy symptoms (such as 
pruritus, hives, vomiting, abdominal pain, asthma, 
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Abstract
Oral immunotherapy (OIT) has been introduced as a new immune-modulating treatment under investigation for food 
allergies. The aim of our study was to evaluate the success of OIT in a cohort of children with milk allergy. These children 
underwent OIT in a clinical practice and were followed for up to ten years. The secondary endpoint was to describe the 
main adverse events during OIT and compare them to those reported in the literature.
Eighty-two milk-allergic children started OIT. According to the OIT endpoint reached after one year, all of the 
children enrolled in the study were divided into four groups: complete desensitization; partial desensitization; step down; 
and stop groups. Any adverse events that occurred during OIT were also recorded.
Of the 82 patients, eight were recruited in the last months of 2010 so they were still ongoing at the end of the study. 
For that reason, they were excluded from the analysis. The majority (73%) of the 74 children evaluated (51 boys, 23 
girls; median age, 7 years; age range, 2–18 years; specific serum IgE for cow’s milk, 36 KUA/L [range, 3–100 KUA/L]; milk 
SPT wheal diameter, 7 mm [range, 2–15 mm]) reached complete (58.1%) or partial (14.9%) desensitization, 9.4% were 
subjected to step down. The remaining 17.6% of the children discontinued OIT because of the occurrence of chronic 
gastroenteric (GE) symptoms (46.1%) or acute asthma (15.3%) following milk intake.
In agreement with the literature, we found that chronic GE symptoms was the main reason for OIT discontinuation. 
OIT represents a valid tool for the treatment of food allergies in children; however, the risk of potential adverse 
reactions, both IgE- and non-IgE-mediated, should be discussed with parents prior to the initiation of OIT.
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or even anaphylaxis) occurs within 30–60 min of 
ingesting the food product. Milk, peanuts, and eggs 
are the most frequent foods involved in pediatric 
cases of food allergies.1 In contrast, a T-cell 
response is considered responsible for non-IgE-
mediated reactions, such as celiac disease, food 
protein-induced colitis or enterocolitis (FPIES), 
and eosinophilic esophagitis (EoE). These reac-
tions are characterized by the delayed onset of pre-
dominantly gastroenteric (GE) symptoms. Thus 
far, the elimination diet remains the first line of 
treatment for these types of food allergies. More 
recently, oral immunotherapy (OIT) has been intro-
duced as a new immune-modulating treatment 
aimed at inducing desensitization in IgE-mediated 
food allergies. OIT raises the tolerance threshold 
and may reduce the risk of severe IgE-mediated 
reactions (anaphylaxis) and improve a patient’s 
quality of life.2,3 In particular, a meta-analysis by 
Nurmatov et al.4 reported a significant reduction in 
the likelihood of reaction at a food challenge fol-
lowing the OIT compared to controls (risk ratio: 
0.21, 95% confidence interval [CI], 0.21–0.38). 
However, there are several obstacles for the use of 
OIT worldwide, including: (1) the possibility of 
acute reactions in any phase of the desensitization 
protocol; (2) uncertainty about long-term efficacy; 
(3) the development of chronic non-IgE-mediated 
food allergies, such as EoE, once the food is rein-
troduced into the diet; and (4) compliance issues 
because a lack of patient compliance could lead to 
severe life-threatening reactions. For all these rea-
sons OIT is still under investigation for food 
allergy. Several approaches have been proposed to 
improve the safety of OIT. These include: research 
on using alternative routes of exposure, modified 
hypoallergenic products and adjuvants for immu-
notherapy as well as on biomarkers and successful 
OIT to facilitate patient selection.5 The aims of our 
study were to evaluate the success of OIT in a 
cohort of 82 children with a severe milk allergy 
and to describe the main adverse events, both acute 
and chronic, during OIT comparing them with 
those reported in the literature.
Patients and methods
Over the course of five years (2005–2010), 82 chil-
dren with a severe allergy to milk started OIT with 
milk based on the protocol of Mori et al.6 All of 
the children underwent skin prick tests (SPT) with 
fresh cow’s milk (30 mg/L), its progressive dilu-
tions with saline solution (1/10 = 3 mg/mL; 1/100 = 
0.3 mg/mL; 1/1000 = 0.03 mg/mL; 1:10,000 = 
0.003 mg/mL; 1/100,000 = 0.0003 mg/mL; 
1/1,000,000 = 0.00003 mg/mL), and serum-specific 
IgE detection (Immunocap) at baseline. The skin 
test is considered to be positive with a wheal skin 
reaction ⩾ 3 mm. We started OIT with the dilution 
immediately below the endpoint dilution (positive 
SPT) and we progressively increased the amount of 
milk administered every 20 min according to Mori 
et al.’s protocol.6 If the child had a reaction to the 
milk, we stopped the procedure for that day and we 
started again the next day using only half of the 
dose that provoked the allergic reaction. The end 
dose was defined as 100–150 mL cow’s milk, and 
this dose was reached in approximately six months. 
Typically, we performed the higher increments at 
the hospital, discharging the patient with half of 
the dosage reached. During oral desensitization 
therapy, the children did not receive pre- or co-
treatment with antihistamines or corticosteroids.
All of the children had a personal history of ana-
phylactic reactions to milk within the last 6–12 
months5 or a severe allergic reaction to very low 
doses of milk (< 0.6 mg of cow’s milk protein) and 
had milk-specific IgE detected in the serum or dur-
ing a SPT.7
An allergy specialist collected the personal med-
ical history of each patient, and the severity of all 
clinical reactions described by the parents was 
evaluated according to the current definition of a 
food allergy.8
Children were tested with a SPT for common 
inhalant and food allergens (i.e. pollen, mites, 
mold, cat and dog epithelia, milk, albumen, soy, 
wheat, cod fish, peanuts, and latex using commer-
cial extracts at 0.1 mg/mL from Alk Abellò, 
Milan, Italy). The positive and negative controls 
for the SPT were obtained using histamine (10 
mg/mL, ALK-Abellò, Milan, Italy) and normal 
saline, respectively.
All of the children who were found to be allergic 
to inhalants and were affected by asthma had con-
trolled asthma prior to the initiation of OIT.9 In 
particular, asthmatic children did not require a 
bronchodilator in the previous six months, and the 
asthma was independent of the pollen season. Both 
parents gave written informed consent before their 
child began milk OIT and were made aware of the 
risks/benefits related to this type of treatment.
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Based on the OIT endpoint reached, all of the 
enrolled children were divided into four groups: 
(1) the complete desensitization group: children 
tolerant to 100–150 mL of cow’s milk; (2) the par-
tial desensitization group: children who tolerated 
2–50 mL of cow’s milk and had never reached 
100–150 mL of cow’s milk; (3) the step-down 
group: children who had to reduce their daily milk 
intake one to two months after reaching complete 
desensitization due to the occurrence of severe 
adverse events; and (4) the stop group: children 
who had to stop OIT because of severe acute or 
chronic reactions independent of the amount of 
milk already reached.
GE, respiratory, and skin symptoms during OIT 
were recorded in a diary and noted as dose-related. 
Acute symptoms were sometimes associated with 
treatments such as epi use, beta agonist, and anti-
histamines use. No endoscopies were performed.
The children were followed for one year (a mean 
time of six months), starting from OIT initiation. 
Those children who are still undergoing OIT were 
recruited in the last few months of 2010.
A 5–10-year follow-up interview by phone was 
performed.
The data were analyzed using a commercially 
available statistical software package (SPSS, 
Chicago, IL, USA). Data were analyzed using the 
Mann–Whitney–Wilcoxon test for independent 
samples. A P value < 0.05 was considered statisti-
cally significant.
Results
Eighty-two children evaluated (52 boys, 30 girls; 
age range, 2–18 years; median age, 7 years). The 
median serum-specific IgE level for cow’s milk in 
the study population was 36 KUA/L (range, 3–100 
KUA/L). The median milk SPT wheal diameter 
was 7 mm (range, 2–15 mm). The atopic status of 
the children in the study is summarized in Table 1. 
Most of our patients (73%) achieved complete 
(43/74; 58.1%) or partial (11/74; 14.9%) desensiti-
zation to milk. After a mean time period of six 
months, the immunotherapy desensitization proto-
col had been discontinued in 17.6% of the children 
after they reached a daily dose in the range of 2–50 
mL of cow’s milk. Reasons for discontinuation 
included chronic GE symptoms (46.1%) and acute 
asthma after milk intake during the OIT protocol 
(15.3%). In addition, 23% of the patients discon-
tinued OIT due to poor compliance and 15.3% due 
to stress (mainly the fear of an adverse reaction) 
(Table 2). The GE symptoms most commonly 
described were abdominal pain, nausea, vomiting, 
reduced appetite, and dysphagia. In addition, 7/74 
patients (9.4%) utilized a step-down protocol due 
to the presence of GE symptoms (71.4%) (Figure 
1). We next examined differences in clinical char-
acteristics among patients who achieved complete 
desensitization, partial desensitization, those who 
had to do the step-down therapy, and those who 
discontinued OIT.
The patients who achieved complete desensitiza-
tion had fewer asthma symptoms at baseline (33% 
versus 100%, P < 0.001) and lower levels of milk-
specific IgE (7.29 KUA/L [3–100] versus 31.4 
KUA/L [12–87], P = 0.013) compared to patients 
with only partial desensitization to milk (Table 1). 
The patients with complete desensitization to milk 
had increased asthma symptoms at baseline (33% 
versus 15.3%, P = 0.16), a lower level of milk-specific 
IgE, as measured by both SPT wheal size (8 mm 
[2–15] versus 10 mm [3–12], P = 0.016) and by 
serum-specific IgE levels (7.29 KUA/L [3–100] 
versus 40.8 KUA/L [3–87], P = 0.004) compared to 
those who discontinued OIT (Table 1). Compared 
with patients who participated in step-down ther-
apy, those who achieved complete desensitization 
had increased asthma symptoms at baseline (33% 
Table 1. Demographic characteristics of the studied population.
Sex (M:F) Median 
age (years) 
[range]
Wheal size 
milk P+P 
(mm) [range]
Milk-specific 
IgE (KUA/L) 
[range]
Aeroallergen-
positive SPT
Baseline respiratory 
symptoms (allergic rhinitis 
or controlled asthma)
Complete desensitization (n = 43) 31:12 8 [2–18] 8 [2–15] 7.29 [3–100] 62% 33%
Partial desensitization (n = 11) 6:5 9 [3–18] 10 [3–12] 31.4 [12–87] 70% 100%
Step down (n = 7) 5:2 7 [3–12] 7 [3–12] 38.8 [3–74] 62.5% 12.5%
OIT discontinuation (n = 13) 9:4 7 [2–17] 10 [3–12] 40.8 [3–87] 77% 15.3%
OIT, oral immunotherapy; P+P, prick by prick; SPT, skin prick test.
Mori et al. 185
versus 12.5%, P < 0.05) and a lower level of milk-
specific serum IgE (7.29 KUA/L [3–100] versus 
38.8 KUA/L [3–74], P = 0.046) (Table 1). Compared 
with patients who discontinued OIT, those who 
achieved partial desensitization had increased 
asthma symptoms at baseline (100% versus 15.3%, 
P < 0.001), a similar level of milk-specific IgE, as 
measured by SPT wheal size (10 mm [3–12] versus 
10 mm [3–12], P = 0.878), and lower levels of 
milk-specific serum IgE (31.4 KUA/L [12–87] ver-
sus 40.8 KUA/L [3–87], P = 0.477). The patients 
also tended to be older (9 years [3–18] versus 7 
years [2–17], not significant) (Table 1). Compared 
with the patients who participated in step-down 
therapy, those who achieved partial desensitization 
to milk had increased asthma symptoms at baseline 
(100% versus 12.5%, P < 0.001), higher levels of 
milk-specific IgE, as measured by SPT wheal size 
(10 mm [3–12] versus 7 mm [3–12], P = 0.395), 
and lower levels of milk-specific IgE, as measured 
by serum-specific IgE (31.4 KUA/L [12–87] versus 
38.8 KUA/L [3–74], P = 0.028) (Table 1). Finally, 
the patients who participated in step-down therapy 
had similar clinical characteristics to those who dis-
continued OIT. Overall, the most common side 
effects that prevented the completion or continua-
tion of OIT were acute asthma and chronic GE 
symptoms. Those who became partially desensi-
tized reported acute respiratory symptoms during 
OIT more frequently (asthma versus GE symptoms: 
63.6% versus 36.3%). In contrast, those who com-
pleted step-down therapy or had to stop OIT devel-
oped chronic GE symptoms (71.4% and 46.1%, 
respectively) more frequently than those who were 
partially desensitized to milk at the end of the study 
(36.3%) (Table 1).
Table 2. Symptoms during OIT and follow-up at 5–10 years based on recall.
Total (n; %) Patients with adverse 
reactions (n; %)
GE vs. asthma (%) FU at 5–10 years/symptoms (n; %)
Complete 
desensitization
43/74 (58.1%) 20 (46.5%): mild symptoms 
(oral allergy syndrome, 
urticaria, rhinitis); 7 (16.2%): 
GE; 12 (27.9%): asthma; 
2 (4.6%): asthma + GE; 2 
(4.6%): anaphylaxis
20.9% vs. 32.5% 30/43 (69.76%): regular milk intake; 
1/43 (2.3%): only baked milk; 12 (28%): 
no information
Partial 
desensitization
11/74 (14.9%) 3 (27.27%): GE; 36.3% vs. 63.6% 4 (36.3%): only baked milk; 7 (63.63%): 
milk avoidance; 3/11 (27.27%): GE 
symptoms; 1/11 (9%) asthma; 1/11 (9%): 
fear; 2/11 (18.18%): urticaria 
 6 (54.54%): asthma;
 1 (9%): asthma + GE;
 1 (9%): anaphylaxis
Step down 7/74 (9.4%) 3 (42.8%): GE; 71.4% vs. 42.8% 1 (14.2%): regular milk intake; 1 (14.2%): 
only baked milk; 2 (28.5%): milk 
products but no milk because of taste 
preference; 2 (28.5%) few milliliters 
of milk because of GE symptoms; 1 
(14.2%): no information 
 2 (28.5%): asthma + 
urticaria + GE;
 1 (14.2%): asthma + 
urticaria;
 1 (14.2%): no 
compliance
OIT 
discontinuation
13/74 (17.6%) 4 (30.76%): GE; 46.1% vs. 15.3% 3 (23.07%): partial desensitization; 5 
(38.46%): milk avoidance; 2 (15.3%): GE 
symptoms; 1 (7.69%): asthma; 2 (15.3%): 
anaphylaxis; 3 (23.07%): no compliance; 
2 (15.3%): no information 
 2 (15.3%): asthma 
+ GE;
 2 (15.3%): stress 
(fear of reactions);
 2 (15.3%): 
anaphylaxis;
 3 (23.07%): no 
compliance
Ongoing 8/82 (9.8%) Not recorded 3 (37.5%): regular milk intake; 1 
(12%): only baked milk; 2 (25%): 
partial desensitization because of GE 
symptoms in one case and asthma in the 
other case; 2 (25%): milk avoidance; 1 
(12.5%): anaphylaxis; 1 (12.5%): fear
GE, gastroenteric; OIT, oral immunotherapy.
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At the 5–10-year follow-up, most of the partici-
pants who had completed OIT continued to con-
sume milk regularly (69.76%); 28% were lost at 
follow-up (Table 2). In contrast, most of the par-
ticipants who were in the partial desensitization 
group tended to avoid milk after the 5–10-year 
period (63.63%). However, even those who had to 
reduce their daily milk intake after a few years 
were still drinking milk in small doses. Among 
those who discontinued OIT, only 23.07% reached 
a partial desensitization to milk after the 5–10-year 
period, and most of those children still had a free 
milk diet (38.46%). Interestingly, those with GE 
symptoms had lower levels of IgE specific to milk 
compared to those who developed asthma (Figure 
1). Approximately one-third of the patients who 
were in the ongoing group during the period of 
recruitment reached complete milk desensitization 
when investigated after ten years. However, they 
were excluded from further analysis.
Discussion
Our results here are consistent with data reported 
in the literature. In fact, previous studies have sug-
gested that children undergoing OIT for food aller-
gies present GE symptoms in approximately 30% 
of cases10 and specifically in 10% of children 
treated with oral desensitization to milk.11,12 Also, 
respiratory symptoms (dyspnea, asthma) have 
been described due to OIT in approximately 10% 
of patients.10 These patients usually require a 
bronchodilator and steroid therapy but rarely stop 
OIT. In our experience, adverse respiratory reac-
tions were the main cause of partial desensitiza-
tion to milk. In agreement with the literature, the 
respiratory symptoms did not cause our patients to 
stop OIT. In our case study, in agreement with the 
literature, we found that chronic GE symptoms 
were the main reason why a patient would stop 
OIT. Interestingly, those who could not achieve 
complete oral desensitization had mainly acute 
reactions (such as anaphylaxis or asthma) as well 
as higher levels of milk-specific IgE. In contrast, 
those who achieved complete desensitization but 
had to step down or stop OIT mainly had GE 
symptoms and lower levels of milk-specific IgE, 
suggesting that there are two mechanisms that can 
lead to OIT failure: one is a failure to induce 
desensitization and stop the IgE-mediated reac-
tion; and the other occurs when IgE-mediated 
reactions are successfully stopped but another 
type of reaction, most likely not mediated by IgE, 
occurs. Patients who are treated with OIT may 
develop immediate and delayed GE complica-
tions.10 The acute symptoms are fairly easy to 
explain as part of an IgE-mediated reaction.13 
However, chronic GE symptoms are more difficult 
to understand. Mounting evidence suggests that 
OIT can induce EoE. In large milk-OIT studies, 
EoE has been reported in 2.7–10.3% of patients.12,14 
The type of symptoms and their chronicity may be 
compatible with the development of EoE in our 
case study. This finding suggests that in children, 
the incidence of EoE following OIT may be higher 
than 2.7%.15 However, as described by Narisety 
et al., not all of the children showing symptoms 
consistent with EoE undergo an esophageal endos-
copy, thus leading to an uncertain diagnosis.16 In 
our case, for example, many of the symptoms were 
so severe that we needed to step down or stop OIT. 
In conclusion, compared to other non-life-threat-
ening adverse reactions, GE events appear to have 
the largest effect on the success of oral desensiti-
zation therapy. Several of the children in our study 
also showed late-onset GE symptoms (i.e. vomit-
ing, abdominal pain) during OIT, with complete 
clinical remission after the discontinuation of OIT. 
For technical reasons, we could not perform 
endoscopies in these patients. Thus, the potential 
diagnosis of EoE remains a conjecture. To date, 
OIT represents a valid tool for the treatment of 
food allergies in children and can improve their 
Figure 1. Differences in P values (P < 0.05 by the Mann–
Whitney–Wilcoxon test) related to prick by prick (P+P) wheal 
diameter (mm) and level of milk-specific IgE (KUA/L) among 
children who develop GE vs. asthmatic symptoms.
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quality of life. However, the risks of potential 
adverse reactions, with both IgE- and non-IgE-
mediated food allergies, should be discussed with 
parents prior to the initiation of OIT. More recently 
OIT with hypoallergenic products or with adju-
vants association could be proposed in high-risk 
patients.5,17
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